Cellebrite DI (CLBT) Cash & Equivalents (2020 - 2025)

Cellebrite DI's Cash & Equivalents history runs 6 years deep, the most recent figure standing at $124.5 million for Q4 2025.

• On a quarterly basis, Cash & Equivalents fell 35.06% year-over-year to $124.5 million in Q4 2025; TTM through Dec 2025 was $124.5 million, a 35.06% decrease from a year earlier, with the FY2025 full-year figure at $124.5 million, down 35.06% from the prior year.
• Cash & Equivalents eased to $124.5 million in Q4 2025 per CLBT's latest filing, from $281.4 million in the prior quarter.
• Across five years, Cash & Equivalents topped out at $281.4 million in Q3 2025 and bottomed at $84.6 million in Q3 2022.
• The 5-year median for Cash & Equivalents is $123.4 million (2024), against an average of $134.1 million.
• Across the five-year window, Cash & Equivalents tumbled 39.96% in 2022 and surged 116.23% in 2023, its largest moves.
• Year by year, Cash & Equivalents stood at $146.0 million in 2021, then sank by 39.96% to $87.6 million in 2022, then jumped by 116.23% to $189.5 million in 2023, then increased by 1.13% to $191.7 million in 2024, then tumbled by 35.06% to $124.5 million in 2025.
• Per Business Quant, the three latest CLBT Cash & Equivalents figures stand at $124.5 million (Q4 2025), $281.4 million (Q3 2025), and $179.2 million (Q2 2025).